The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
Titel:
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission
Auteur:
Wei, Andrew H. Döhner, Hartmut Pocock, Christopher Montesinos, Pau Afanasyev, Boris Dombret, Hervé Ravandi, Farhad Sayar, Hamid Jang, Jun Ho Porkka, Kimmo Selleslag, Dominik Sandhu, Irwindeep Turgut, Mehmet Giai, Valentina Ofran, Yishai Kizil Cakar, Merih Botelho de Sousa, Aida Rybka, Justyna Frairia, Chiara Borin, Lorenza Beltrami, Germana Cermak, Jaroslav Ossenkoppele, Gert J. La Torre, Ignazia Skikne, Barry Kumar, Keshava Dong, Qian Beach, CL Roboz, Gail J.